Skip to content
Screener

Erasca, Inc. ERAS Common Stock

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Amgen logo
AmgenAMGN
2.8B0.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$21K+16.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
400M+100%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$9K0.0%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2026 and December 31, 2025; 310,806,888 and 284,159,076 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively3128
Additional paid-in capital1,469,8451,216,724
Accumulated other comprehensive (loss) income(699)628
Accumulated deficit(1,075,649)(892,209)
Total stockholders' equity393,528325,171

Item 1. Financial Statements.

FAQ

What is Erasca, Inc.'s common stock?
Erasca, Inc. (ERAS) reported common stock of $31K in Q1 2026.
How has Erasca, Inc.'s common stock changed year-over-year?
Erasca, Inc.'s common stock increased by 10.7% year-over-year, from $28K to $31K.
What is the long-term trend for Erasca, Inc.'s common stock?
Over 5 years (2020 to 2025), Erasca, Inc.'s common stock has grown at a 56.3% compound annual growth rate (CAGR), from $3K to $28K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Erasca, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude